Review



normal tissue ihc data v.23.0  (Human Protein Atlas)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Human Protein Atlas normal tissue ihc data v.23.0
    (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain <t>IHC</t> <t>data</t> (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.
    Normal Tissue Ihc Data V.23.0, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+tissue+ihc+data+v%2E23%2E0/bio_rxiv__2024__12__11__627962-372-0-7?v=Human+Protein+Atlas
    Average 90 stars, based on 1 article reviews
    normal tissue ihc data v.23.0 - by Bioz Stars, 2026-07
    90/100 stars

    Images

    1) Product Images from "Pan-cancer N -glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers"

    Article Title: Pan-cancer N -glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers

    Journal: bioRxiv

    doi: 10.1101/2024.12.11.627962

    (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain IHC data (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.
    Figure Legend Snippet: (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain IHC data (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.

    Techniques Used: Glycoproteomics, RNA Sequencing, MANN-WHITNEY



    Similar Products

    normal tissue ihc data v.23.0  (Human Protein Atlas)
    90
    Human Protein Atlas normal tissue ihc data v.23.0
    (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain <t>IHC</t> <t>data</t> (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.
    Normal Tissue Ihc Data V.23.0, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/normal+tissue+ihc+data+v%2E23%2E0/bio_rxiv__2024__12__11__627962-372-0-7?v=Human+Protein+Atlas
    Average 90 stars, based on 1 article reviews
    normal tissue ihc data v.23.0 - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain IHC data (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.

    Journal: bioRxiv

    Article Title: Pan-cancer N -glycoproteomic atlas of patient-derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers

    doi: 10.1101/2024.12.11.627962

    Figure Lengend Snippet: (A &B) Contingency tables used to determine the likelihood of detecting a clinical (A) ADC and (B) CAR T target in the PDX human tumor N -glycoproteome against all other surface proteins in the human proteome. P-values were calculated using a Fisher’s exact test. (C) Normal tissue toxicity scoring system. (D) Distribution of full body normal tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Jiang et al., (left), Human Protein Atlas (middle) and GTEx RNA-seq data (right). (E) Distribution of normal brain tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Tushaus et al., (left), Human Protein Atlas brain IHC data (middle) and Human Protein Atlas brain RNA-seq data (right). (F) Distribution of normal heart tissue abundance or detection frequency of PDX target candidates (purple) vs solid tumor clinical immunotherapy targets (grey) in Berg Luecke et al., (left) and Doll et al., (middle & right). (D-F) P-values from unpaired Mann-Whitney U tests.

    Article Snippet: Normal tissue IHC data were downloaded from Human Protein Atlas (v.23.0) .

    Techniques: Glycoproteomics, RNA Sequencing, MANN-WHITNEY